Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amgen Inc. is conducting a Phase 4 clinical trial titled ‘A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.’ The study aims to assess the long-term safety of avacopan in treating ANCA-associated vasculitis, a condition that causes inflammation of blood vessels.
The intervention being tested is Avacopan, an oral medication intended to provide long-term treatment for ANCA-associated vasculitis. The study includes three groups: one receiving Avacopan with standard care, another receiving Avacopan followed by a placebo, and a third group receiving a placebo with standard care.
This study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. The primary purpose is treatment, and both participants and investigators are masked to the treatment assignments.
The study began on October 2, 2023, with an estimated primary completion date in 2025 and the last update submitted on October 24, 2025. These dates are crucial for tracking the study’s progress and expected outcomes.
This update could positively impact Amgen’s stock performance by reinforcing investor confidence in the company’s pipeline, especially if the results demonstrate Avacopan’s long-term safety and efficacy. The study’s outcome could also influence the competitive landscape in the treatment of ANCA-associated vasculitis.
The study is ongoing, with further details available on the ClinicalTrials portal.